BRITISH COLUMBIA, Canada--(BUSINESS WIRE)--InNexus Biotechnology Inc. (OTCBB:IXSBF) (TSX VENTURE:IXS), a drug development company commercializing the next generation of monoclonal antibodies based on its Dynamic Cross Linking (DXL™) technology, today announced that the company’s management will host a teleconference and Web cast on Thursday, August 16 at 4:00 PM EDT to provide additional insight into its first pre-clinical candidate, DXL625 (CD20), for the treatment of non-Hodgkin’s lymphoma.
